Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-470P is a pseudogene related to the U6 family of small nuclear RNAs (snRNAs). U6 snRNA is an essential component of the spliceosome complex responsible for removing introns from pre-mRNA in the cell nucleus, and it is highly conserved across eukaryotes[1][3]. The U6 family also includes many pseudogenes (non-functional gene copies) in vertebrates, which likely have no known functional role and do not code for proteins or functional RNAs[3][5]. Pseudogenes like RNU6-470P do not act as therapeutic targets (such as receptors, enzymes, transporters, or transcription factors), and there is no evidence linking this pseudogene to disease mechanisms, drug interactions, or biomarker utility[3][5]. The naming convention (numbered "470") simply reflects genomic annotation and does not imply unique biological activity. There are no known therapeutic, diagnostic, or mechanistic implications associated with RNU6-470P; its presence is primarily of genomic annotation interest. This target is therefore not a therapeutic target, and the entry is considered incorrect for drug discovery or target biology applications[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 470, pseudogene (RNU6-470P).